Holders over time
- ABVX
- TMO
| Quarter | ABVX | TMO |
|---|---|---|
| Q3 2020 | none listed holders, n.a. | 29 holders, $38.9bn |
| Q4 2020 | none listed holders, n.a. | 33 holders, $39.2bn |
| Q1 2021 | none listed holders, n.a. | 35 holders, $36.5bn |
| Q2 2021 | none listed holders, n.a. | 33 holders, $38.3bn |
| Q3 2021 | none listed holders, n.a. | 32 holders, $42.6bn |
| Q4 2021 | none listed holders, n.a. | 38 holders, $50.1bn |
| Q1 2022 | none listed holders, n.a. | 32 holders, $43.2bn |
| Q2 2022 | none listed holders, n.a. | 33 holders, $38.9bn |
| Q3 2022 | none listed holders, n.a. | 26 holders, $34.3bn |
| Q4 2022 | none listed holders, n.a. | 29 holders, $37.0bn |
| Q1 2023 | none listed holders, n.a. | 35 holders, $37.1bn |
| Q2 2023 | none listed holders, n.a. | 39 holders, $33.5bn |
| Q3 2023 | none listed holders, n.a. | 39 holders, $32.6bn |
| Q4 2023 | none listed holders, n.a. | 41 holders, $32.7bn |
| Q1 2024 | none listed holders, n.a. | 30 holders, $34.1bn |
| Q2 2024 | none listed holders, n.a. | 38 holders, $30.6bn |
| Q3 2024 | none listed holders, n.a. | 30 holders, $33.8bn |
| Q4 2024 | none listed holders, n.a. | 36 holders, $27.6bn |
| Q1 2025 | none listed holders, n.a. | 31 holders, $24.2bn |
| Q2 2025 | none listed holders, n.a. | 39 holders, $18.8bn |
| Q3 2025 | 6 holders, $483m | 32 holders, $21.9bn |
| Q4 2025 | 10 holders, $743m | 32 holders, $29.9bn |
| Q1 2026 | 8 holders, $257m | 34 holders, $24.4bn |
| Q2 2026 | 8 holders, $482m | 36 holders, $26.4bn |
Abivax SA
- Holders
- 8
- Reported value
- $257m
- Buyers
- 7
- Sellers
- 15
Breadth -8 among 91 comparable managers.
Thermo Fisher Scientific Inc
- Holders
- 34
- Reported value
- $24.4bn
- Buyers
- 23
- Sellers
- 23
Breadth 0 among 91 comparable managers.
Who holds both, Q1 2026
Both (5)
Farallon Capital Management LLC, Holocene Advisors LP, Janus Henderson Group Ltd, Point72 Asset Management LP, Woodline Partners LP
Only ABVX (3)
Caxton Associates LLP, ExodusPoint Capital Management LP, Hudson Bay Capital Management LP
Only TMO (29)
AllianceBernstein LP, Arrowstreet Capital LP, Artisan Partners LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., D1 Capital Partners LP, Dodge & Cox, Fidelity (FMR LLC), GAMCO Investors Inc, Glenview Capital Management LLC, Invesco Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Investments LP, and 4 more
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.